274 related articles for article (PubMed ID: 8216696)
1. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.
Sundblad C; Hedberg MA; Eriksson E
Neuropsychopharmacology; 1993 Sep; 9(2):133-45. PubMed ID: 8216696
[TBL] [Abstract][Full Text] [Related]
2. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial.
Sundblad C; Modigh K; Andersch B; Eriksson E
Acta Psychiatr Scand; 1992 Jan; 85(1):39-47. PubMed ID: 1546547
[TBL] [Abstract][Full Text] [Related]
3. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
[TBL] [Abstract][Full Text] [Related]
4. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
Eriksson E; Hedberg MA; Andersch B; Sundblad C
Neuropsychopharmacology; 1995 Apr; 12(2):167-76. PubMed ID: 7779245
[TBL] [Abstract][Full Text] [Related]
5. [Psychiatric and psychological aspects of premenstrual syndrome].
Limosin F; Ades J
Encephale; 2001; 27(6):501-8. PubMed ID: 11865558
[TBL] [Abstract][Full Text] [Related]
6. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?
Wikander I; Sundblad C; Andersch B; Dagnell I; Zylberstein D; Bengtsson F; Eriksson E
J Clin Psychopharmacol; 1998 Oct; 18(5):390-8. PubMed ID: 9790157
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.
Steiner M; Steinberg S; Stewart D; Carter D; Berger C; Reid R; Grover D; Streiner D
N Engl J Med; 1995 Jun; 332(23):1529-34. PubMed ID: 7739706
[TBL] [Abstract][Full Text] [Related]
8. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.
Freeman EW; Sondheimer SJ; Sammel MD; Ferdousi T; Lin H
J Clin Psychiatry; 2005 Jun; 66(6):769-73. PubMed ID: 15960573
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled study of the effects of L-tryptophan in patients with premenstrual dysphoria.
Steinberg S; Annable L; Young SN; Liyanage N
Adv Exp Med Biol; 1999; 467():85-8. PubMed ID: 10721042
[TBL] [Abstract][Full Text] [Related]
11. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
[TBL] [Abstract][Full Text] [Related]
12. Effect of clomipramine on premenstrual syndrome.
Eriksson E; Lisjö P; Sundblad C; Andersson K; Andersch B; Modigh K
Acta Psychiatr Scand; 1990 Jan; 81(1):87-8. PubMed ID: 2330836
[TBL] [Abstract][Full Text] [Related]
13. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability.
Landén M; Erlandsson H; Bengtsson F; Andersch B; Eriksson E
Neuropsychopharmacology; 2009 Feb; 34(3):585-92. PubMed ID: 18596686
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.
Eriksson E; Ekman A; Sinclair S; Sörvik K; Ysander C; Mattson UB; Nissbrandt H
J Clin Psychopharmacol; 2008 Apr; 28(2):195-202. PubMed ID: 18344730
[TBL] [Abstract][Full Text] [Related]
15. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome.
Halbreich U; Smoller JW
J Clin Psychiatry; 1997 Sep; 58(9):399-402. PubMed ID: 9378691
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
Halbreich U; Bergeron R; Yonkers KA; Freeman E; Stout AL; Cohen L
Obstet Gynecol; 2002 Dec; 100(6):1219-29. PubMed ID: 12468166
[TBL] [Abstract][Full Text] [Related]
17. A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial.
Schmidt K; Weber N; Steiner M; Meyer N; Dubberke A; Rutenberg D; Hellhammer J
Clin Nutr ESPEN; 2018 Apr; 24():22-30. PubMed ID: 29576358
[TBL] [Abstract][Full Text] [Related]
18. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.
Sundblad C; Wikander I; Andersch B; Eriksson E
Eur Neuropsychopharmacol; 1997 Aug; 7(3):201-6. PubMed ID: 9213079
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
Landén M; Nissbrandt H; Allgulander C; Sörvik K; Ysander C; Eriksson E
Neuropsychopharmacology; 2007 Jan; 32(1):153-61. PubMed ID: 17035933
[TBL] [Abstract][Full Text] [Related]
20. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group.
Thys-Jacobs S; Starkey P; Bernstein D; Tian J
Am J Obstet Gynecol; 1998 Aug; 179(2):444-52. PubMed ID: 9731851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
